Evommune EVMN
NYSE EVMN
$8.64 +0.80 (+10.14%)
As of: Nov 11, 2026 · 3:59 PM EST

Evommune (EVMN) Operating Leases (2024 - 2026)

Updated

Evommune's Operating Leases was $6.44 million in Q2 2026, down 4.8% from the prior quarter.

Analysis

Evommune (EVMN) Operating Leases (2024 - 2026) Analysis & Trends

At the end of FY2025, Operating Leases at Evommune came in at $1.29 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Evommune 285.17 Mn -352.34 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 6.44 Mn
Mar 31, 2026 6.77 Mn
Dec 31, 2025 1.29 Mn
Sep 30, 2025 160,000.00
Dec 31, 2024 487,000.00
API Access

Evommune Operating Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-leases&ticker=EVMN&period=max&api_key=YOUR_API_KEY